Compare Eli Lilly And Co (LLY) vs Banco Santander SA (SAN) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Banco Santander (SAN) trades at $13.31, down 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.41, beating expectations, but missed in prior quarters. Revenue for 2025 was $60.02B with a net income margin of 26.72%. Recent news highlights Santander's AI initiatives, acquisition of Webster Bank, and becoming Spain's most valuable company. Cash flow trends show operational challenges, with net cash flow negative in recent years.

Outlook is cautiously optimistic with a 64% analyst buy rating, targeting efficiency gains and AI-driven value. Risks include regulatory probes, declining cash flows, and high debt levels. The stock offers a dividend yield with the recent $0.15 payout, but investors should weigh operational improvements against financial volatility and macroeconomic pressures in the banking sector.